Ranibizumab Pro Re nata versus Dexamethasone in the Management of Ischemic Retinal Vein Occlusion: Post-hoc Analysis from the COMRADE Trials

ABSTRACT Purpose: To compare ischemia-related clinical outcomes in patients treated with either ranibizumab pro re nata (PRN) or single dexamethasone implant in the Branch Retinal Vein Occlusion (COMRADE-B) or Central Retinal Vein Occlusion (COMRADE-C) trials. Methods: A post-hoc analysis of the Phase IIIb, 6-month, multicenter, double-masked, randomized, COMRADE-B and COMRADE-C trials. Change over 6 months in retinal ischemia status (central avascular [CA] zone and peripheral nonperfusion [PNP]), mean best-corrected visual acuity (BCVA), the development of shunt vessels and neovascularization, and frequency of laser therapy were assessed in retinal vein occlusion (RVO) patients treated with either ranibizumab 0.5 mg PRN or single dexamethasone 0.7 mg implant, as per European labels, in the COMRADE-B (N = 244; ranibizumab, 126, dexamethasone, 118) or COMRADE-C (N = 243; ranibizumab, 124, dexamethasone, 119) trials. BCVA progression in ischemic vs. non-ischemic patients based on the ischemia assessment at month 6 was carried out. Results: Visual acuity (VA) gains from baseline to month 6 were higher with ranibizumab than with dexamethasone in both patients with central ischemia and those with peripheral retinal nonperfusion, independent of the type of RVO (branch or central). The presence of CA and PNP had a significant impact on VA gain over 6 months in CRVO patients (p < .0001), while there was no significant impact in BRVO. Ranibizumab was associated with less new ischemia than dexamethasone. Central RVO patients treated with dexamethasone received more laser treatments over the 6 months than those treated with ranibizumab, while there was no difference in the frequency of laser therapy between the branch RVO treatment groups. Conclusions: VA gain over six months in ranibizumab-treated RVO patients is not affected by ischemia, and is associated with less development of new ischemia during the first 6 months of treatment and equal or fewer laser treatments than dexamethasone implant.

[1]  N. Eter,et al.  Head‐to‐head comparison of ranibizumab PRN versus single‐dose dexamethasone for branch retinal vein occlusion (COMRADE‐B) , 2018, Acta ophthalmologica.

[2]  A. Wenzel,et al.  Sustained Benefits of Ranibizumab with or without Laser in Branch Retinal Vein Occlusion: 24-Month Results of the BRIGHTER Study. , 2017, Ophthalmology.

[3]  N. Eter,et al.  Clinical Efficacy and Safety of Ranibizumab Versus Dexamethasone for Central Retinal Vein Occlusion (COMRADE C): A European Label Study. , 2016, American journal of ophthalmology.

[4]  S. Sivaprasad,et al.  Predictors of Outcome in Patients with Neovascular Age-Related Macular Degeneration Switched from Ranibizumab to 8-Weekly Aflibercept. , 2016, Ophthalmology.

[5]  Glenn J Jaffe,et al.  Morphology and Visual Acuity in Aflibercept and Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration in the VIEW Trials. , 2016, Ophthalmology.

[6]  Sobha Sivaprasad,et al.  HYPERREFLECTIVE FOCI AS AN INDEPENDENT VISUAL OUTCOME PREDICTOR IN MACULAR EDEMA DUE TO RETINAL VASCULAR DISEASES TREATED WITH INTRAVITREAL DEXAMETHASONE OR RANIBIZUMAB , 2016, Retina.

[7]  A. Wenzel,et al.  Individualized Stabilization Criteria-Driven Ranibizumab versus Laser in Branch Retinal Vein Occlusion: Six-Month Results of BRIGHTER. , 2016, Ophthalmology.

[8]  A. Wenzel,et al.  Individualized Ranibizumab Regimen Driven by Stabilization Criteria for Central Retinal Vein Occlusion: Twelve-Month Results of the CRYSTAL Study. , 2016, Ophthalmology.

[9]  S. Sivaprasad,et al.  The Royal College of Ophthalmologists Guidelines on retinal vein occlusions: executive summary , 2015, Eye.

[10]  S. Kachi,et al.  Significant Correlation between Retinal Venous Tortuosity and Aqueous Vascular Endothelial Growth Factor Concentration in Eyes with Central Retinal Vein Occlusion , 2015, PloS one.

[11]  M. Varano,et al.  DEXAMETHASONE IMPLANT FOR MACULAR EDEMA SECONDARY TO ISCHEMIC RETINAL VEIN OCCLUSIONS , 2015, Retina.

[12]  A. Cruess,et al.  Optimal Treatment of Retinal Vein Occlusion: Canadian Expert Consensus , 2015, Ophthalmologica.

[13]  C. Ehlken,et al.  Increased Expression of Angiogenic and Inflammatory Proteins in the Vitreous of Patients with Ischemic Central Retinal Vein Occlusion , 2015, PloS one.

[14]  Rishi P. Singh,et al.  COLLATERAL VESSEL PRESENCE IN BRANCH AND CENTRAL RETINAL VEIN OCCLUSIONS AND THEIR IMPACT ON VISUAL ACUITY AND ANATOMICAL GAINS: A Retrospective Analysis , 2014, Retina.

[15]  S. Sadda,et al.  AREA OF PERIPHERAL RETINAL NONPERFUSION AND TREATMENT RESPONSE IN BRANCH AND CENTRAL RETINAL VEIN OCCLUSION , 2014, Retina.

[16]  Bernd Junker,et al.  Efficacy and Safety of Intravitreal Therapy in Macular Edema Due to Branch and Central Retinal Vein Occlusion: a Systematic Review , 2013, PloS one.

[17]  P. Campochiaro,et al.  Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. , 2013, Ophthalmology.

[18]  I. Scott,et al.  SCORE STUDY REPORT 12: Development of Venous Collaterals in the Score Study , 2013, Retina.

[19]  M. Michaelis,et al.  Comparison of cytokine levels from undiluted vitreous of untreated patients with retinal vein occlusion , 2012, Acta ophthalmologica.

[20]  T. Mimura,et al.  Vitreous inflammatory factors and serous retinal detachment in central retinal vein occlusion: a case control series , 2011, Journal of Inflammation.

[21]  John R. Ledford,et al.  Zinc supplementation alters airway inflammation and airway hyperresponsiveness to a common allergen , 2011, Journal of Inflammation.

[22]  C. Ehlken,et al.  Levels of VEGF but not VEGF(165b) are increased in the vitreous of patients with retinal vein occlusion. , 2011, American journal of ophthalmology.

[23]  Ingrid U. Scott,et al.  Retinal vein occlusion. , 2010, British medical journal.

[24]  S. Harper,et al.  VEGF-A165b is cytoprotective and antiangiogenic in the retina. , 2010, Investigative ophthalmology & visual science.

[25]  S. Harper,et al.  Recombinant human VEGF165b inhibits experimental choroidal neovascularization. , 2010, Investigative ophthalmology & visual science.

[26]  Jean-Pierre Hubschman,et al.  Ultra wide-field angiographic characteristics of branch retinal and hemicentral retinal vein occlusion. , 2010, Ophthalmology.

[27]  D. Finkelstein,et al.  Argon laser photocoagulation for macular edema in branch vein occlusion. , 1986, Ophthalmology.

[28]  R F Woolson,et al.  Ocular neovascularization with retinal vascular occlusion-III. Incidence of ocular neovascularization with retinal vein occlusion. , 1983, Ophthalmology.

[29]  T. Wong,et al.  Clinical practice. Retinal-vein occlusion. , 2010, The New England journal of medicine.

[30]  J. Jonas,et al.  Retinal vein occlusions. , 2010, Developments in ophthalmology.

[31]  S. Bearelly,et al.  Controversy in the Management of Retinal Venous Occlusive Disease , 2004, International ophthalmology clinics.

[32]  Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group. , 1997, Archives of ophthalmology.

[33]  Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group. , 1984, American journal of ophthalmology.